Evidence map›Paper›PMID 19270260›Full record

Trial reportBlood2009

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Paul J Martin, Barry E Storer, Scott D Rowley, Mary E D Flowers, Stephanie J Lee, Paul A Carpenter, John R Wingard, Paul J Shaughnessy, Marcel P DeVetten, Madan Jagasia and 9 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00089141 phase3terminatednot on this map

A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease

TypeinterventionalSponsorMartin, PaulRan2004 to 2008Enrolled151ConditionsCancerArmsmycophenolate mofetil, placebo
NCT06756061 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease

TypeinterventionalSponsorByung-Sik ChoRan2025 to 2029Enrolled88ConditionsGVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell TransplantationArmsPrednisone + Jakavi(ruxolitinib), Prednisone
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014
    Trial
  13. Trial
  14. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012
    Trial
  15. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 2 countries.

Paul J MartinFred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. pmartin@fhcrc.org
Barry E Storer
Scott D Rowley
Mary E D Flowers
Stephanie J Lee
Paul A Carpenter
John R Wingard
Paul J Shaughnessy
Marcel P DeVetten
Madan Jagasia
Joseph W Fay
Koen van Besien
Vikas Gupta
Carrie Kitko
Laura J Johnston
Richard T Maziarz
Mukta Arora
Pamala A Jacobson
Daniel Weisdorf
Fred Hutch Cancer Center · USUniversity of Minnesota · USUniversity of Washington · USBaylor University Medical Center · USCHRISTUS Transplant Institute · USHackensack University Medical Center · USOregon Health & Science University · USPrincess Margaret Hospital · NZStanford University · USUniversity of Chicago · USUniversity of Florida · USUniversity of Michigan–Ann Arbor · USUniversity of Minnesota System · USUniversity of Nebraska at Omaha · USVanderbilt University · US

Funding

Mycophenylate Mofetil for Treatment of Chronic GVHDR01CA098906 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MARTIN, PAUL J · 2003 to 2008
$2.3M
Optimizing Stem Cell Transplant for CancerK23CA096622 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JACOBSON, PAMALA A · 2002 to 2006
$610k
NCI NIH HHS CA98906NCI NIH HHS K23 CA096622NCI NIH HHS R01 CA098906
6 · The paper itself

Abstract

We conducted a double-blind, randomized multicenter trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment of chronic graft-versus-host disease (GVHD). The primary endpoint was resolution of chronic GVHD and withdrawal of all systemic treatment within 2 years, without secondary treatment. Enrollment of 230 patients was planned, providing 90% power to observe a 20% difference in success rates between the 2 arms. The study was closed after 4 years because the interim estimated cumulative incidence of success for the primary endpoint was 23% among 74 patients in the MMF arm and 18% among 77 patients in the control arm, indicating a low probability of positive results for the primary endpoint after completing the study as originally planned. Analysis of secondary endpoints showed no evidence of benefit from adding MMF to the systemic regimen first used for treatment of chronic GVHD. The estimated hazard ratio of death was 1.99 (95% confidence interval, 0.9-4.3) among patients in the MMF arm compared with the control arm. MMF should not be added to the initial systemic treatment regimen for chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00089141 on August 4, 2004.

Indexed as

Cause of DeathChronic DiseaseDouble-Blind MethodFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansKarnofsky Performance StatusMaleMiddle AgedMycophenolic AcidSurvival RateTreatment OutcomeMycophenolic Acid

Identifiers

PMID19270260
PMCPMC2686178
OpenAlexW2062576298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.